Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 195-213

  Wu, Xinle ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA KLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; HEPARIN; KLOTHO PROTEIN; UNCLASSIFIED DRUG; GROWTH PROMOTOR;

ARTICLE; BINDING SITE; CANCER GROWTH; CARCINOGENESIS; GLUCOSE METABOLISM; HUMAN; LIVER CANCER; METABOLIC REGULATION; MITOGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; REVIEW;

MUS MUSCULUS;

AMINO ACID SEQUENCE; ANIMALS; FIBROBLAST GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859519165     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_13     Document Type: Article

References (65)

1. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 2008; 5:42-48
2. Fukumoto S. Actions and mode of actions ofFGF19 subfamily members. Endocr J 2008; 55:23-31
3. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009; 9:805-810
4. WuX, Ge H, Gupte J et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 2007; 282:29069-29072
5. Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression ofbetaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity ofFGF19 and FGF21.J Biol Chem2007; 282:26687-26695
6. Lin BC, Wang M, Blackmore C et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282:27277-27284
7. Holt JA, Luo G, Billin AN et al. Definition of a novel growth factor-dependent signal cascade for the suppression ofbile acidbiosynthesis. Genes Dev 2003; 17:1581-1591
8. Micanovic R, Raches DW, Dunbar JD et al. Different roles of N- and C- termini in the functional activity ofFGF21. J Cell Physiol 2009; 219:227-234
9. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116-129
10. Nicholes K, Guillet S, Tomlinson E et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160:2295-2307
11. Ogawa Y, Kurosu H, Yamamoto M et al. BetaKlotho is required for metabolic activity of fibroblast growth factor21. Proc Natl Acad SciUSA 2007; 104:7432-7437
12. Tomlinson E, Fu L, John L et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143:1741-1747
13. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115:1627-1635
14. Wu X, Ge H, Lemon B et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285:5165-5170
15. Wu X, Ge H, Lemon B et al. Separating mitogenic andmetabolic activities of fibroblast growth factor 19 (FGF19). Proc NatlAcad SciUSA 2010; 107:14158-14163
16. Suzuki M, Uehara Y, Motomura-Matsuzaka K et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22:1006-1014
17. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974; 249:123-127
18. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8:235-253
19. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125:105-117
20. Krejci P, Prochazkova J, Bryja V et al. Molecular pathology of the fibroblast growth factor family. Hum Mutat 2009; 30:1245-1255
21. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23:18-20
22. di Martino E, LHote CG, Kennedy W et al. Mutant fibroblast growth factor receptor 3 induces intracellular signaling andcellulartransformationinacell type-andmutation-specificmanner. Oncogene2009; 28:4306-4316
23. Naski MC, Wang Q, Xu J et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996; 13:233-237
24. Streit S, Bange J, Fichtner A et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004; 111:213-217
25. Wang J, Stockton DW, IttmannM. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10:6169-6178
26. Wang J,Yu W, CaiY et al. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10:847-856
27. Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009; 299:72-78
28. Plotnikov AN, Schlessinger J, Hubbard SR et al. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98:641-650
29. Furdui CM, Lew ED, Schlessinger J et al. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 2006; 21:711-717
30. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-149
31. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417-3428
32. Katoh M, Katoh M. Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human. Int J Mol Med 2003; 12:45-50
33. Katoh M. WNT and FGF gene clusters (review). Int J Oncol 2002; 21:1269-1273
34. Desnoyers LR, Pai R, Ferrando RE et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27:85-97
35. Pai R, Dunlap D, Qing J et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008; 68:5086-5095
36. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225
37. Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics ofFGF23. Bone 2007; 40:1190-1195
38. Zhang X, Ibrahimi OA, Olsen SK et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-15700
39. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51
40. Ito S, Kinoshita S, Shiraishi N et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000; 98:115-119
41. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774
42. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123
43. Kharitonenkov A, Dunbar JD, Bina HA et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008; 215:1-7
44. Wu X, Ge H, Lemon B et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad SciUSA 2009; 106:14379-14384
45. Xie MH, Holcomb I, Deuel B et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11:729-735
46. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16:107-137
47. Wu X, Lemon B, Li X et al. C-terminal tail of FGF19 determines its specificity toward Klotho coreceptors. J Biol Chem 2008; 283:33304-33309
48. Yie J, Hecht R, Patel J et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 2009; 583:19-24
49. Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43:629-640
50. Schlessinger J, Plotnikov AN, Ibrahimi OA et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFRbinding and dimerization. Mol Cell 2000; 6:743-750
51. Nishimura T, Utsunomiya Y, Hoshikawa M et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999; 1444:148-151
52. Yu C, Wang F, Jin C et al. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 2005; 280:17707-17714
53. Choi M, Moschetta A, Bookout AL et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12:1253-1255
54. Fu L, John LM, Adams SH et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145:2594-2603
55. Wu X, Li Y. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging 2009; 1:1023
56. Huang X, Yang C, Luo Y et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 56:2501-2510
57. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009; 284:11110-11120
58. Coskun T, Bina HA, Schneider MA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149:6018-6027
59. Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58:250-259
60. Huang X, Yu C, Jin C et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006; 45:934-942
61. Sasaki H, Okuda K, Kawano O et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 2008; 20:1125-1130
62. Ho HK, Pok S, Streit S et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target fortherapeutic intervention. JHepatol 2009; 50:118-127
63. Roidl A, Berger HJ, Kumar S et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15:2058-2066
64. Huang X, Yang C, Jin C et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009; 48:553-562
65. Luo Y, Yang C, Lu W et al. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem 2010; 285:30069-30078